IDT Australia Limited

IDT

AU000000IDT0

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 02:10:50 2024-05-30 am EDT			5-day change	1st Jan Change
0.1 ^AUD	+5.26%		+4.17%	-9.09%

May. 06	IDT Australia Secures Victorian Government Funding for Cancer Medication Production Facility	MT
Apr. 16	IDT Australia Signs Master Service Agreement with Sanofi	MT

IDT Australia Ltd Announces the Cessation of Graeme Kaufman as Director

November 17, 2019 at 11:58 pm EST

IDT Australia Ltd. announced the cessation of Graeme Kaufman as director effective 18 November 2019.

Latest news about IDT Australia Limited

IDT Australia Secures Victorian Government Funding for Cancer Medication Production Facility	May. 05	MT
IDT Australia Signs Master Service Agreement with Sanofi	Apr. 15	MT
IDT Australia Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 20	CI
Invion Nears Clinical Trial of Cancer Photodynamic Therapy with Drug Substance Production	Nov. 21	MT
IDT Australia Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-28	CI
IDT Australia Raises AU$2 Million Via Share Purchase Plan	23-07-20	MT
IDT Australia Limited Provides Preliminary Unaudited Revenue Update for the Three Months to End June 2023	23-07-09	CI
IDT Australia to Open AU$2 Million Share Purchase Plan; Shares Rise 3%	23-06-21	MT
IDT Australia Completes First Tranche of AU$5 Million Placement	23-06-11	MT
IDT Australia Raises AU$5 Million for Capex Program; Shares Fall 28%	23-06-05	MT
IDT Australia Limited Reports Sales Results for the Third Quarter Ended March 2023	23-04-26	CI
IDT Australia Achieves Expansion of License to Manufacture Advanced Therapies	23-03-28	MT
IDT Achieves Key Milestone with TGA License Upgrade	23-03-27	CI
IDT Australia Transitions Interim CEO to Permanent Role	23-03-02	MT
IDT Australia Limited Announces the Appointment of Paul McDonald as Chief Executive Officer	23-03-01	CI
IDT Australia Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-22	CI
IDT Australia Chairman to Retire	22-12-21	MT
IDT Australia Limited Announces Board Changes	22-10-09	CI
IDT Australia Names Acting CFO	22-09-27	MT
IDT Australia Limited Announces Appointment of Mark Licciardo as Company Secretary	22-09-27	CI
IDT Australia Limited Announces Appointment of Mahendran Vasanthakumar as Acting CFO	22-09-27	CI
IDT Australia Limited Announces Executive Changes	22-09-14	CI
IDT Australia Limited Reports Earnings Results for the Full Year Ended June 30, 2022	22-08-29	CI
MedAdvisor Names Finance Chief	22-07-25	MT
IDT Australia's CFO Resigns	22-07-21	MT

IDT Australia Limited is a pharmaceutical manufacturing company. The Company is engaged in the supply of products and provision of research and development and other technical services within the pharmaceutical and allied industries. Its business includes research and development, active pharmaceutical ingredient (API) and finished dosage form manufacture (FDF), clinical and commercial, project management, chemical services, analytical chemistry, pharmacy services, pharmaceutical development in all dosage forms, clinical packaging and regulatory affairs services. Its Current Good Manufacturing Practice (cGMP) manufacturing facilities produces both API and FDF across the medicinal cannabis manufacturing space. It also provides a full-scale service for new drug development and scale-up, commercial active drug manufacture as well as a variety of oral and injectable finished drug dose forms. Its analytical laboratories offer medicinal cannabis cGMP testing.

Sector

Biotechnology & Medical Research

Calendar

2024-08-26 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
IDT AUSTRALIA LIMITED	-9.09%	23.34M
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.26%	21.96B
GENMAB A/S	-8.63%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B
INSMED INCORPORATED	+77.64%	8.87B